Abstract 36P
Phase I clinical trials are an essential step for the development of new anticancer treatments. Next-generation phase I trials investigating novel drugs led to consistent improvements in terms of response rates and survival of the enrolled pts. The aim of our study is to evaluate the outcomes of patients enrolled in phase I trials testing targeted therapies (TT), immunotherapy (IT), and combinations.